Allscripts Healthcare Solutions’ Investor Day Review
<p>RBC Capital analysts provided their views on <a href='https://financialmodelingprep.com/financial-summary/MDRX'>Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)</a> following the company’s virtual investor day.</p>
<p>Given the company's H1/22 sale of its hospital/large practice businesses, which represented the majority of revenue and around half of 2021 EBITDA, the company hosted an investor day to educate the market on its remaining/go-forward business—Veradigm. </p>
<p>Along with a detailed look at each component and respective growth drivers, management also reaffirmed its 2022 guidance provided with the divestiture announcement in March. </p>
<p>Analysts at RBC Capital said they were encouraged by the heightened focus on the company’s higher-growth offerings and confident it has the balance sheet to support it. The analysts maintained their outperform rating and $22 price target on the company’s shares.</p>

NASDAQ:MDRX